Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TSEN34 is a catalytic subunit of the tRNA splicing endonuclease complex, required for accurate excision of introns from precursor tRNA molecules in eukaryotic cells. It cleaves at the 3′ splice site and also interacts with other complex subunits (notably TSEN2, TSEN15, and TSEN54) to facilitate tRNA maturation and efficient protein translation. TSEN34's function extends to mRNA 3′-end processing through association with additional factors, thus linking tRNA and mRNA processing pathways. Mutations in TSEN34 result in pontocerebellar hypoplasia (PCH) type 2C, leading to developmental delay, neurological deficits, and intellectual disability, demonstrating its essential role in brain development and cellular homeostasis. No drugs are currently known to directly target TSEN34, and any potential therapeutic modulation is limited by its critical cellular functions and associated safety risks.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on tRNA splicing endonuclease subunit 34 (TSEN34).